131941-21-4

Basic information

• Product Name: Pyridine, 2-(1-methylethyl)-5-nitro- (9CI)
• Synonyms: Pyridine, 2-(1-methylethyl)-5-nitro- (9CI);Pyridine, 2-(1-methylethyl)-5-nitro-;2-(1-Methylethyl)-5-nitropyridine
• CAS NO: 131941-21-4
• Molecular Formula: C8H10N2O2
• Molecular Weight: 166.1772
• Product Categories: ISOPROPYL;Pyridines
• Mol File: 131941-21-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 246.831 °C at 760 mmHg
• Flash Point: 103.08 °C
• Appearance: /
• Density: 1.149 g/cm³
• Refractive Index: 1.536
• Storage Temp.: 2-8°C
• PKA: 1.81±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-(1-methylethyl)-5-nitro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-(1-methylethyl)-5-nitro- (9CI)(131941-21-4)
• EPA Substance Registry System: Pyridine, 2-(1-methylethyl)-5-nitro- (9CI)(131941-21-4)

Safety Data

• Hazardous Substances Data: 131941-21-4(Hazardous Substances Data)

Usage

Uses

2-Isopropyl-5-nitropyridine is a useful reagent for nucleophilic reactions of electron-deficient pyridone derivatives.

InChI:InChI=1/C8H10N2O2/c1-6(2)8-4-3-7(5-9-8)10(11)12/h3-6H,1-2H3

Upstream product

• 563-80-4 3-methyl-butan-2-one 
• 14150-94-8 3,5-dinitro-1-methyl-2-pyridone 

Downstream Products

• 405103-02-8 2-isopropyl-5-aminopyridine 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.